Mathieu Lane

Mathieu Lane is an experienced finance professional with a strong background in healthcare investment banking and corporate development. Currently, Mathieu Lane serves in Corporate Development at Thermo Fisher Scientific since 2024, following a tenure as Head of Healthcare Investment Banking at Berenberg Capital Markets from 2023 to 2024. Prior to that, Mathieu Lane was Chief Financial Officer at eTheRNA immunotherapies from 2021 to 2022, overseeing financial operations for a US-based Belgian mRNA platform. Mathieu Lane's career in investment banking includes a significant role as Managing Director in the Healthcare (Biopharma) Investment Banking Group at Guggenheim Securities from 2010 to 2021, and a position as Partner and Finance Director at SR One Capital Management in 2009. Earlier experience includes serving as Vice President at Bear Stearns & Co. from 2001 to 2008 and as a Senior Research Associate in Gene Therapy R&D at Genzyme from 1994 to 1999. Mathieu Lane holds a Master of Business Administration in Finance and Accounting from NYU Stern School of Business, earned between 1999 and 2001.